COVID-19 Vaccine Safety First Year Findings in Adolescents. 4/21/2023. Hesse EM. Pediatrics.

This paper reports data obtained via v-safe (a smartphone-based reporting system for reactions to the vaccine)  and VAERS (Vaccine Adverse Event Reporting System of the CDC and FDA)  from 12-17 year old recipients of at least 1 dose of Pfizer mRNA vaccine between 12/14/2020 and 5/10/2022. The v-safe data comes from 172,032 participants, 30% of whom were vaccinated in May 2021. The most common reaction was pain at the injection site (60%). The VAERS data include 20,240 reported events, of which 92% were non-serious. Using 32,268,525 doses administered as the denominator, the authors include a table of the rate per million doses of adverse events of special interest including myocarditis in 17.7 per million, although the rate was 84 per million for the second dose in 16-17 year olds.

The material on this website is provided for informational purposes and does not constitute medical advice. New knowledge is added daily and may change over time. Opinions expressed should not be construed as representing IARS policy or recommendations. References and links to third parties do not constitute an endorsement or warranty by IARS.